SEARCH

SEARCH BY CITATION

References

  • 1
    Gravel NR, Searle NR, Sahab PG, Carrier M. Sedation in critically ill patients: practical recommendations. CNS Drugs 1999; 11: 922.
  • 2
    Riker RR, Fraser GL. Altering intensive care sedation paradigms to improve patient outcomes. Critical Care Clinics 2009; 25: 52738, viii–ix.
  • 3
    Westmoreland CL, Hoke JF, Sebel PS, Hug CC Jr, Muir KT. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993; 79: 893903.
  • 4
    Kapila A, Glass PS, Jacobs JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology 1995; 83: 96875.
  • 5
    Breen D, Wilmer A, Bodenham A, et al. Offset of pharmacodynamic effects and safety of remifentanil in intensive care unit patients with various degrees of renal impairment. Critical Care 2004; 8: R2130.
  • 6
    Bonnet MP, Minville V, Asehnoune K, et al. Glycine and ammonia plasma concentrations during sedation with remifentanil in critically ill patients. Intensive Care Medicine 2007; 33: 117982.
  • 7
    Belhadj Amor M, Ouezini R, Lamine K, Barakette M, Labbéne I, Ferjani M. Daily interruption of sedation in intensive care unit patients with renal impairment: remifentanil-midazolam compared to fentanyl-midazolam. Annales Françaises d’Anesthésie et de Réanimation 2007; 26: 10414.
  • 8
    Chinachoti T, Kessler P, Kirkham A, Werawatganon T. Remifentanil vs morphine for patients in intensive care unit who need short-term mechanical ventilation. Journal of Medical Association of Thailand 2002; 85 (Suppl. 3): S84857.
  • 9
    Carrer S, Bocchi A, Candini M, Donega L, Tartari S. Short term analgesia based sedation in the intensive care unit: morphine vs. Remifentanil + morphine. Minerva Anestesiologica 2007; 73: 327.
  • 10
    Baillaard C, Cohen Y, Toumelin PL, et al. Remifentanil-Midazolam compared to sufentanil-midazolam for ICU long term sedation. Annales Françaises d’Anesthésie et de Réanimation 2005; 24: 4806.
  • 11
    Rauf K, Vohra A, Fernandez-Jimenez P, O’Keeffe N, Forrest M. Remifentanil infusion in association with fentanyl-propofol anaesthesia in patients undergoing cardiac surgery: effects on morphine requirement and postoperative analgesia. British Journal of Anaesthesia 2005; 95: 61115.
  • 12
    Dahaba AA, Grabner T, Rehak PH, List WF, Metzler H. Remifentanil versus morphine analgesia and sedation for mechanically ventilated critically ill patients: a randomized double blind study. Anesthesiology 2004; 101: 6406.
  • 13
    Breen D, Karabinis A, Malbrain M, et al. Decreased duration of mechanical ventilation when comparing analgesia-based sedation using remifentanil with standard hypnotic-based sedation for up to 10 days in intensive care unit patients: a randomised trial. Critical Care 2005; 9: R20010.
  • 14
    Muellejans B, Matthey T, Scholpp J, Schill M. Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial. Critical Care 2006; 10: R91.
  • 15
    Muellejans B, López A, Cross MH, Bonome C, Morrison L, Kirkham AJ. Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial. Critical Care 2004; 8: R111.
  • 16
    Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial. Critical Care 2004; 8: R26880.
  • 17
    Rozendaal FW, Spronk PE, Snellen FF, et al.; UltiSAFE investigators. Remifentanil-propofol analgo-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, open-label study in the Netherlands. Intensive Care Medicine 2009; 35: 2918.
  • 18
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996; 17: 112.
  • 19
    Matthews JN, Altman DG. Interaction 3: how to examine heterogeneity. British Medical Journal 1996; 313: 862.
  • 20
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003; 327: 55760.
  • 21
    Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 45563.
  • 22
    Egan TD. Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Clinical Pharmacokinetics 1995; 29: 8094.
  • 23
    Cox EH, Langemeijer MW, Gubbens-Stibbe JM, et al. The comparative pharmacodynamics of remifentanil and its metabolic, GR90291, in a rat electroencephalographic model. Anaesthesiology 1999; 90: 53544.
  • 24
    Egan TD, Lemmens HJ, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (G187084B) in healthy adult male volunteers. Anesthesiology 1993; 79: 88192.